GBIM
GLOBEIMMUNE INC
stock OTC

we are a biopharmaceutical company established in 1995 focused on developing products for the treatment of cancer and infectious diseases based on our proprietary tarmogen ® platform. tarmogens activate the immune system by stimulating a subset of white blood cells called t cells that destroy infected or malignant cells, in contrast to traditional vaccines which predominately stimulate antibody production. we believe that our tarmogen platform has applicability to a number of diseases, and may enable us to develop a broad portfolio of products. we have four tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. tarmogens target the molecular profile that distinguishes a diseased cell from a normal cell. we have designed tarmogens to target specific intracellular and extracellular proteins, or antigens, that play a role in oncology and infectious diseases which represent unmet medical needs. collaborations with biopharmaceutical compan